Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Cabaletta Bio

Clinical trials sponsored by Cabaletta Bio, explained in plain language.

Cabaletta Bio CABA NASDAQ

A clinical-stage biotechnology company developing CAR T cell therapies for autoimmune diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 5 Not yet finished but already full! 1 Completed 1

MS trial withdrawn before it began: CAR T-Cell hope on hold

Disease control Terminated

This study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …

Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC